Evidence map›Paper›PMID 32040476›Full record

ArticlePloS one2020

MicroRNA-155 governs SHIP-1 expression and localization in NK cells and regulates subsequent infiltration into murine AT3 mammary carcinoma.

Wendy M Kandell, Sarah S Donatelli, Thu Le Trinh, Alexandra R Calescibetta, Tina So, Nhan Tu, Danielle L Gilvary, Xianghong Chen, Pingyan Cheng, William A Adams and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Phenotypic Switching of VSMCs in the Development of CVDs: Focus on miRs.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Wendy M KandellDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Sarah S DonatelliDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Thu Le TrinhDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Alexandra R CalescibettaDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Tina SoDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Nhan TuDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Danielle L GilvaryDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Xianghong ChenDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Pingyan ChengDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
William A AdamsDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Yin-Kai ChenDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Jinhong LiuDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Julie Y DjeuDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Sheng WeiDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.
Erika A EksiogluDepartment of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States of America.ORCID 0000-0003-4458-7192
Moffitt Cancer Center · USUniversity of South Florida · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Tumor Immunology Training Program -1 T32 CA115308-A1T32CA115308 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI WRIGHT, KENNETH LYNN · 2007 to 2017
$2.8M
Modulation of the S100A9/CD33 Pathway by the Flavonoids ICA and ICT on the TumorK01CA187020 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI EKSIOGLU, ERIKA ADRIANA · 2014 to 2018
$456k
NCI NIH HHS K01 CA187020NCI NIH HHS P30 CA076292NCI NIH HHS T32 CA115308
6 · The paper itself

Abstract

NK cell migration and activation are crucial elements of tumor immune surveillance. In mammary carcinomas, the number and function of NK cells is diminished, despite being positively associated with clinical outcome. MicroRNA-155 (miR-155) has been shown to be an important regulator of NK cell activation through its interaction with SHIP-1 downstream of inhibitory NK receptor signaling, but has not been explored in regard to NK cell migration. Here, we explored the migratory potential and function of NK cells in subcutaneous AT3 in mice lacking miR-155. Without tumor, these bic/miR-155-/- mice possess similar numbers of NK cells that exhibit comparable surface levels of cytotoxic receptors as NK cells from wild-type (WT) mice. Isolated miR-155-/- NK cells also exhibit equivalent cytotoxicity towards tumor targets in vitro compared to isolated WT control NK cells, despite overexpression of known miR-155 gene targets. NK cells isolated from miR-155-/- mice exhibit impaired F-actin polymerization and migratory capacity in Boyden-chamber assays in response chemokine (C-C motif) ligand 2 (CCL2). This migratory capacity could be normalized in the presence of SHIP-1 inhibitors. Of note, miR-155-/- mice challenged with mammary carcinomas exhibited heightened tumor burden which correlated with a lower number of tumor-infiltrating NK1.1+ cells. Our results support a novel, physiological role for SHIP-1 in the control of NK cell tumor trafficking, and implicate miR-155 in the regulation of NK cell chemotaxis, in the context of mammary carcinoma. This may implicate dysfunctional NK cells in the lack of tumor clearance in mice.

Indexed as

AnimalsCell Line, TumorCell MovementChemotaxisFemaleGene Knockout TechniquesKiller Cells, NaturalLymphocytes, Tumor-InfiltratingMammary Neoplasms, ExperimentalMiceMice, Inbred C57BLMice, KnockoutMicroRNAsPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesSignal TransductionInpp5d protein, mouseMicroRNAsMirn155 microRNA, mousePhosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases

Identifiers

PMID32040476
PMCPMC7010306
OpenAlexW3006382472

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.